Antibody Engineering And The Bispecific Revolution | Dr. Tahamtan Ahmadi, MD, Ph.D., Executive Vice President, Chief Medical Officer and Head of Experimental Medicines, Genmab
Send us Fan Mail What if we stopped thinking about antibodies as simply drugs that bind to one target - and started thinking about them as engineered molecular machines? Today we're talking about a bispecific antibody that targets both EGFR and LGR5, and asking whether that kind of antibody engineering could actually change the treatment landscape for head and neck cancer. Dr. Tahamtan Ahmadi, MD, Ph.D. is Executive Vice President, Chief Medical Officer and Head of Experimental Medicines at ...